2023ÄêÅ·Ö޷ΰ©´ó»á£¨ELCC£©½«ÓÚ2023Äê3ÔÂ29ÈÕ-4ÔÂ1ÈÕÔÚµ¤Âó¸ç±¾¹þ¸ùÒÔÏßÉÏÏßÏÂÏàÍŽáµÄÐÎʽ¾ÙÐС£¡£¡£¡£¡£¡£¡£±¾´ÎELCC´ó»á±¨µÀÓÉÖйú´ó½ר¼Ò×÷ΪµÚÒ»×÷Õß»òͨѶ×÷ÕßµÄEGFR-TKIÏà¹ØÑо¿¹²11ƪ£¬£¬£¬£¬£¬ÆäÖаüÀ¨º²É­ÖÆÒ©×ÔÖ÷Á¢ÒìÒ©¼×»ÇËá°¢ÃÀÌæÄáƬ(ÉÌÆ·Ãû£º°¢ÃÀÀÖ^?)Ïà¹ØЧ¹û5ƪ£¬£¬£¬£¬£¬Õ¼×ÜƪÊýµÄ45%£¬£¬£¬£¬£¬ÔÚËùÓÐEGFR-TKIÖÐÃûÁеÚÒ»£¬£¬£¬£¬£¬ÔÚ¹ú¼ÊÎę̀·¢³öÖйúÔ­Á¢ÒìÒ©×îÇ¿Òô£¡

ELCCÊǷΰ©ÁìÓò±¶ÊܹØ×¢µÄÖ÷ҪѧÊõ¾Û»áÖ®Ò»£¬£¬£¬£¬£¬ÓÉÅ·ÖÞÖ×ÁöÄÚ¿Æѧ»á£¨ESMO£©Óë¹ú¼Ê·Î°©Ñо¿Ð­»á£¨IASLC£©ÍŽá¾ÙÐУ¬£¬£¬£¬£¬ÖÂÁ¦ÓÚÔö½ø¿ÆѧÉú³¤¡¢Èö²¥½ÌÓýºÍÌá¸ßÈ«ÌìÏ·ΰ©×¨¼ÒµÄÁÙ´²Êµ¼ù¡£¡£¡£¡£¡£¡£¡£±¾½ìELCCÄê»á£¬£¬£¬£¬£¬°¢ÃÀÌæÄá5ƪժҪÈëÑ¡£¬£¬£¬£¬£¬°üÀ¨3ƪÑо¿Êý¾ÝºÍ2ƪÑо¿Éè¼Æ£¬£¬£¬£¬£¬»®·Ö´øÀ´ÔÚ·ÇСϸ°û·Î°©£¨NSCLC£©°ÐÏòÍŽá·ÅÁÆ¡¢¸¨ÖúÖÎÁƺ͸߼ÁÁ¿ÄÔתÒÆÖÎÁÆÆ«ÏòµÄ×îÐÂÑо¿Ï£Íû¡£¡£¡£¡£¡£¡£¡£

ͨÀýÕªÒª

ÕªÒª±àºÅ£º18P

Stereotactic radiotherapy(SRT) in combination with Aumolertinib to treat intracranial oligometastatic Non-Small Cell Lung Cancer (NSCLC): An update of the phase II, prospective study

°¢ÃÀÌæÄáÍŽáÁ¢Ì嶨Ïò·ÅÁÆ(SRT)ÖÎÁÆ­ÄÚ¹ÑתÒÆÐÔNSCLC£ºÒ»ÏîÇ°Õ°ÐÔIIÆÚÁÙ´²Ñо¿

×÷Õߣº·®•G/³Â¼ÑÑÞ½ÌÊÚ£¨¸´µ©´óѧÁ¥ÊôÖ×ÁöÒ½Ôº£©

¼ò½é£º±¾Ñо¿£¨NCT04519983£©Ö¼ÔÚ̽Ë÷°¢ÃÀÌæÄáÍŽáSRTÖÎÁÆ­ÄÚ¹ÑתÒÆÐÔNSCLCµÄÁÆЧºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£¹²ÄÉÈë35Àý¾ßÓÐEGFRÃô¸ÐÍ»±äµÄ­ÄÚ¹ÑתÒÆ»¼Õߣ¬£¬£¬£¬£¬½ÓÊÜ°¢ÃÀÌæÄá110mgÖÎÁÆ£¬£¬£¬£¬£¬Ö±µ½Â­ÄÚ¼²²¡Ï£Íû£¬£¬£¬£¬£¬ÔÚ­ÄÚ¹ÑÏ£Íûºó½ÓÊÜSRTÖÎÁÆ£¨32¨C40Gy£¬£¬£¬£¬£¬8Gy/f£©¡£¡£¡£¡£¡£¡£¡£Ö÷ÒªÖÕµãÊÇ­Äڿ͹ۻº½âÂÊ£¨iORR£©¡£¡£¡£¡£¡£¡£¡£Êý¾Ý×èֹʱ£¬£¬£¬£¬£¬32Àý»¼Õß¿ÉÆÀ¹ÀÁÆЧ£¬£¬£¬£¬£¬Ëæ·Ãʱ¼äΪ3-16¸öÔ¡£¡£¡£¡£¡£¡£¡£ËùÓв¡Ô°üÀ¨Â­ÄںͭÍ⣩¶ÔÖÎÁƾùµÖ´ï²¿·Ö»º½â£¨PR£©£¬£¬£¬£¬£¬ iORR´ï100%£»£»£»£»£»Î´±¬·¢¡Ý3¼¶²»Á¼ÊÂÎñ¡£¡£¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£º97P

Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I-III non-small cell lung cancer with high-risk pathological factors

°¢ÃÀÌæÄḨÖúÖÎÁƾßÓиßΣ²¡ÀíÒòËصÄEGFRÍ»±äI-IIIÆÚNSCLC

×÷ÕߣºÉòΤÓð½ÌÊÚ£¨Äþ²¨ÊÐÒ½ÁÆÖÐÐÄÀî»ÝÀûÒ½Ôº£©¡¢Éòº£²¨½ÌÊÚ£¨Äþ²¨ÊеڶþÒ½Ôº£©

¼ò½é£º±¾Ñо¿¹²ÄÉÈë115ÀýÍêÈ«Çгý¡¢I-IIIÆÚ¡¢º¬ÊµÌ塢΢ÈéÍ·»òÖØ´óÏÙÌåÒòËصķÎÏÙ°©»¼Õߣ¬£¬£¬£¬£¬·ÖΪA×飺EGFRÑôÐÔ£¬£¬£¬£¬£¬½ÓÊÜ°¢ÃÀÌæÄá110 mgÖÎÁÆ£¨n=45£©£¬£¬£¬£¬£¬B×飺EGFRÑôÐÔ£¬£¬£¬£¬£¬ÊӲ죨n=25£©£¬£¬£¬£¬£¬C×飺EGFRÒõÐÔ»òδ֪£¬£¬£¬£¬£¬ÊӲ죨n=45£©¡£¡£¡£¡£¡£¡£¡£Ö÷ÒªÖÕµãÊÇÎÞ²¡ÉúÑÄÆÚ£¨DFS£©¡£¡£¡£¡£¡£¡£¡£Êý¾Ý×èֹʱ£¬£¬£¬£¬£¬A×é¡¢B×éºÍC×é1ÄêDFSÂÊ»®·ÖΪ100%¡¢88%ºÍ93%¡£¡£¡£¡£¡£¡£¡£ÓëEGFRÒõÐÔ»òδ֪Ïà±È£¬£¬£¬£¬£¬EGFRÍ»±äÑôÐÔ»¼Õ߸´·¢Âʸü¸ß¡£¡£¡£¡£¡£¡£¡£Î´±¬·¢¡Ý3¼¶²»Á¼ÊÂÎñ¡£¡£¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£º98P

Adjuvant aumolertinib in resected EGFR-Mutated Non-Small-Cell Lung Cancer: a multiple-center real-world experience

°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÍ»±äµÄNSCLC£ºÒ»Ïî¶àÖÐÐÄÕæʵÌìÏÂÑо¿

×÷Õߣººú¼á½ÌÊÚ£¨Õã½­´óѧҽѧԺÁ¥ÊôµÚÒ»Ò½Ôº£©

¼ò½é£º±¾Ñо¿Ö¼ÔÚÆÀ¹ÀNSCLC»¼ÕßÊõºóʹÓð¢ÃÀÌæÄḨÖúÖÎÁƵĺã¾ÃÁÆЧºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£¹²ÄÉÈë215ÀýI¨CIIIÆÚ¡¢¾ßÓÐEGFRÍ»±ä¡¢¾­ÓɸùÖÎÊÖÊõºóµÄ·ÇСϸ°û·ÎÏÙ°©»¼Õß¡£¡£¡£¡£¡£¡£¡£½ÓÊÜ°¢ÃÀÌæÄá110 mg/dÖÎÁÆ£¬£¬£¬£¬£¬ÆÀ¹ÀDFS¡¢Çå¾²ÐÔºÍÄÍÊÜÐÔ¡£¡£¡£¡£¡£¡£¡£ËùÓл¼Õß¾ùËæ·Ã6¸öÔÂÒÔÉÏ£¬£¬£¬£¬£¬40Àý»¼ÕßËæ·Ã2ÄêÒÔÉÏ¡£¡£¡£¡£¡£¡£¡£Êý¾Ý×èֹʱ£¬£¬£¬£¬£¬ËùÓл¼Õß¾ùδ·ºÆðÖÐÊàÉñ¾­ÏµÍ³×ªÒÆ£¬£¬£¬£¬£¬Ö»ÓÐ1Àý»¼Õß·ºÆð¹ÇתÒÆ¡£¡£¡£¡£¡£¡£¡£2ÄêDFSÂÊ´ï99%¡£¡£¡£¡£¡£¡£¡£Î´±¬·¢¡Ý3¼¶²»Á¼ÊÂÎñ£¬£¬£¬£¬£¬Çå¾²ÐÔÓÅÒì¡£¡£¡£¡£¡£¡£¡£

ÕýÔÚ¾ÙÐÐÖеÄÁÙ´²Ñо¿

ÕªÒª±àºÅ£º80TiP

High-dose Aumolertinib Versus Osimertinib in EGFR T790M+ NSCLC Patients With Brain Metastases (ATTACK)

¸ß¼ÁÁ¿°¢ÃÀÌæÄá±ÈÕÕ°ÂÏ£ÌæÄáÖÎÁÆEGFR T790M+ NSCLCÄÔתÒÆ»¼Õߣ¨ATTACK£©

×÷ÕߣºÂ½Ë´½ÌÊÚ£¨ÉϺ£ÊÐÐØ¿ÆÒ½Ôº£©

¼ò½é£ºATTACKÑо¿£¨NCT04870190£©ÊÇÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú±ÈÕÕ¡¢¿ª·ÅµÄÁÙ´²Ñо¿£¬£¬£¬£¬£¬Ö¼ÔÚÒ»/¶þ´úEGFR-TKIÖÎÁÆÏ£ÍûºóµÄEGFR T790MÍ»±äÑôÐÔÍíÆÚNSCLC°éÄÔתÒÆ»¼ÕßÖУ¬£¬£¬£¬£¬ÆÀ¼Û¸ß¼ÁÁ¿°¢ÃÀÌæÄá±ÈÕÕ°ÂÏ£ÌæÄáµÄÁÆЧºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£ÄâÄÉÈë232Àý»¼Õߣ¬£¬£¬£¬£¬°´1:1µÄ±ÈÀýËæ»ú·ÖÅɵ½¸ß¼ÁÁ¿£¨165mg£©°¢ÃÀÌæÄáÖÎÁÆ×é»ò°ÂÏ£ÌæÄáÖÎÁÆ×é¡£¡£¡£¡£¡£¡£¡£Ö÷ÒªÖÕµãΪiPFS£¬£¬£¬£¬£¬´ÎÒªÖÕµã°üÀ¨iORR¡¢Â­ÄÚDCR£¨iDCR£©¡¢Â­ÍâPFS£¨ePFS£©¡¢Â­ÍâORR£¨eORR£©¡¢Â­ÍâDCR£¨eDCR£©¡¢PFS¡¢ORR¡¢DCR¡¢OSºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£º104TiP

MRD Evaluation of Aumolertinib in EGFR Mutation-positive stage IB and stage IA2-3 NSCLC After Complete Surgical Resection: A Multicenter, Open-lable, Single-arm Study (ASSIST)

MRDÆÀ¹À¼×»ÇËá°¢ÃÀÌæÄáÓÃÓÚEGFRÍ»±äÑôÐÔµÄIBÆÚºÍIA2-3ÆÚ½þÈóÐÔNSCLCÊõºó¸¨ÖúÖÎÁƵĶàÖÐÐÄ¡¢¿ª·Å¡¢µ¥±ÛÁÙ´²Ñо¿£¨ASSIST£©

×÷Õߣº³Ì³¬½ÌÊÚ£¨ÖÐɽ´óѧÁ¥ÊôµÚÒ»Ò½Ôº£©

¼ò½é£ºASSISTÑо¿£¨ChiCTR2200063184£©Ö¼ÔÚ½ÏÁ¿Ï¸Ð¡²ÐÁô²¡ÔMRD£©ÑôÐÔºÍMRDÒõÐÔ»¼ÕßʹÓð¢ÃÀÌæÄáÒ»Á¬ÖÎÁƵÄDFS²î±ð£¬£¬£¬£¬£¬²¢Ì½Ë÷»ùÓÚMRD¾«×¼¼ì²â¶Ô¸öÌ廯¸¨Öú°ÐÏòÖÎÁƵÄÖ¸µ¼×÷Óᣡ£¡£¡£¡£¡£¡£ÄâÄÉÈë130ÀýEGFRÍ»±äµÄIBÆÚ»òIA2-3ÆÚNSCLCÊõºó»¼Õߣ¬£¬£¬£¬£¬½ÓÊÜ°¢ÃÀÌæÄá110 mg¸¨ÖúÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£Æ¾Ö¤ÊõºóÁ½´ÎMRD¼ì²âЧ¹û¾ÙÐзֲ㣬£¬£¬£¬£¬ÎÞÂÛMRDÑôÐÔÕÕ¾ÉMRDÒõÐÔ»¼Õߣ¬£¬£¬£¬£¬¾ù¸øÓèÒ»Á¬µÄ°¢ÃÀÌæÄáÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£Ñо¿Ö÷ÒªÖÕµãΪ3ÄêDFSÂÊ£¬£¬£¬£¬£¬´ÎÒªÖÕµã°üÀ¨4ÄêºÍ5ÄêDFSÂÊ¡¢OSºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£

Äú¿ÉµÇ¼ÒÔÏÂÍøÖ·£¬£¬£¬£¬£¬Éó²é2023 ELCCÄê»áÑо¿Ð§¹ûµÄÏêϸÐÅÏ¢£º

https://cslide.ctimeetingtech.com/elcc23hybrid/attendee/confcal_1/presentation/list